A double-blind, randomized, placebo controlled, partial 4-way crossover interaction study to examine the effects of a single dose of haloperidol or placebo on THC-induced CNS effects in healthy male volunteers

A double-blind, randomized, placebo controlled, partial 4-way crossover interaction study to examine the effects of a single dose of haloperidol or placebo on THC-induced CNS effects in healthy male volunteers - Study to examine the effects of haloperidol on THC in healthy males

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON32373

Enrollment

Registered

2007-10-03

Start date

2007-12-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psychosen denkstoornis) hallucinaties psychosis (wanen

Interventions

The two drugs used in the study are haloperidol 3 mg orally administrated and THC intrapulmonary (2, 4, 6 mg with intervals of 90 minutes) or the placebos of both drugs.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: See protocol paragraph 3.2

Exclusion criteria

Exclusion criteria: See protocol paragraph 3.3

Design outcomes

Primary

Measure	Time frame
To examine the effects of haloperidol on the CNS-effects of THC compared to placebo.	—

Secondary

Measure	Time frame
To examine the CNS-effects of haloperidol To examine the CNS-effects of THC	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)